Recordati披露2026年上半年业绩，罕见病业务增长但全年指引仅维持不变

How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
Introduction & Market Context
Recordati (XMIL:REC) presented its first-half 2026 results on July 29, 2026, reporting continued momentum in its rare disease portfolio and improved profitability metrics despite foreign exchange headwinds. The Italian pharmaceutical group, which operates in approximately 150 countries with around 4,700 employees, delivered revenue that slightly exceeded market expectations in the second quarter, with actual revenue of $681.35 million versus a forecast of $676.7 million.
The company’s stock traded at $51.40 following the announcement, down marginally by 0.06% from the previous close of $51.43, suggesting investors had largely anticipated the solid operational update. At current levels, shares remain near the upper end of their 52-week range of $43.78 to $55.10, reflecting confidence in the company’s execution across its specialty and primary care, and rare diseases portfolios.
First Half 2026 Performance Highlights
Recordati reported net revenue of €1,410.8 million for the first half of 2026, representing a 6.6% increase on a reported basis and 9.1% growth on a like-for-like basis at constant exchange rates. The company faced a foreign exchange headwind of approximately 2.6%, primarily from the U.S. dollar and Turkish lira.
As shown in the following overview of key financial metrics, the company delivered growth across all major profitability measures:
EBITDA increased 8.8% to €540.2 million, with the margin expanding to 38.3% from 37.5% in the prior year period. This margin improvement reflected better product mix, the absence of acquisition-related inventory charges that affected the prior year, and disciplined cost management. Adjusted net income rose 6.7% to €349.9 million, maintaining a 24.8% margin on revenue.
The company generated free cash flow of €299.4 million, an improvement of €42.6 million compared to the first half of 2025. This stronger cash generation supported the company’s balance sheet, with net debt falling to below 1.9 times EBITDA, providing what CFO Mike McClellan described as "considerable financial flexibility" for future investments and potential business development opportunities.
The following comprehensive income statement breakdown illustrates the growth trajectory across all key metrics:
Gross profit increased 14.3% to €1,008.8 million, with gross margin expanding to 71.5% from 66.7% in the prior year. On an adjusted basis, which excludes non-cash charges from purchase price allocation inventory step-ups, adjusted gross profit grew 8.5% to €1,008.8 million with a 71.5% margin. Operating income surged 26.6% to €419.2 million, while adjusted operating income increased 10.2% to €434.8 million, representing a 30.8% margin.
Rare Diseases: Primary Growth Engine
The rare diseases segment continued to serve as Recordati’s primary growth driver, with revenue reaching €603.9 million in the first half, up 17.1% on a reported basis and 22.0% on a like-for-like basis at constant exchange rates. This performance was led by double-digit expansion in both the endocrinology and hema-oncology therapeutic areas.
The following chart illustrates the robust performance across the rare diseases portfolio:
Within endocrinology, Isturisa (osilodrostat) delivered exceptional growth of 58.0%, reaching €178.8 million in revenue. CEO Rob Koremans attributed this performance to "robust patient acquisition and conversion and strong commercial execution," with the company’s expanded customer-facing teams now fully in place. Management noted that conversion rates improved significantly in the second quarter, with more than 20% additional conversions versus the first quarter, driven by lower insurance-related churn and smoother conversion among repeat prescribers.
Signifor (pasireotide) contributed €68.8 million, up 5.8%, benefiting from higher volumes in the U.S. market. The company is advancing a Phase 2 clinical trial to assess Signifor’s efficacy in post-bariatric hypoglycemia, with plans to finalize a Phase 3 development program by year-end 2026.
In hema-oncology, the segment grew 14.8%, driven by strong momentum across multiple products. Enjaymo (sutimlimab) posted 31.1% growth to €91.0 million, with expansion across the U.S., Japan, and EMEA regions. The company plans to initiate a Phase 3 trial for Enjaymo in immune thrombocytopenic purpura (ITP) in early 2027, potentially expanding the product’s addressable market.
Qarziba (dinutuximab beta) grew 6.5% to €83.7 million across geographies, while Sylvant (siltuximab) increased 6.4% to €48.1 million. The metabolic segment faced softer performance, declining 8.0% to €125.9 million, primarily due to phasing of Carbaglu shipments across geographies and slightly lower Panhematin demand in the U.S., though management expects a return to growth in the second half.
Specialty & Primary Care: Navigating Headwinds
The specialty and primary care segment, which includes pharmaceutical chemicals, generated €806.8 million in revenue, essentially flat compared to the prior year. Excluding chemicals, pharmaceutical revenue was €773.5 million, down 0.1% on a reported basis but up 0.6% on a like-for-like basis at constant exchange rates.
The following breakdown shows the segment’s performance across therapeutic areas:
Management characterized this as "resilient performance despite one-off headwinds and low cough & cold season." The segment faced several temporary challenges, including the loss of the Cardicor license, a weak cough and cold season in key markets, and phasing effects in certain product categories.
The cardiovascular franchise posted modest growth of 0.7% to €161.5 million. This reflected a strong €14 million contribution from Vazkepa (ethyl-icosapent), which the company acquired rights to in certain markets, and continued growth of pitavastatin products, which increased 28.5% to €36.2 million. These gains were partially offset by the Cardicor loss and lower sales of mature products including metoprolol and lercanidipine, partly due to phasing of sales orders.
Urology products grew 1.0% to €209.3 million, with Eligard (leuprorelin acetate) delivering strong 9.5% growth to €69.1 million. Management noted that Eligard benefited from a competitor stock-out in Turkey, though this boost is considered temporary and not expected to continue indefinitely. This gain was largely offset by a one-off effect from Tergynan’s re-launch in Russia during 2025.
The gastrointestinal portfolio increased 3.9% to €135.8 million, driven mainly by Procto-Glyvenol performance. However, the cough and cold category declined 9.7% to €53.6 million due to an unusually mild season in the first half in key markets, a seasonal factor expected to normalize over time.
Regional Performance and Geographic Mix
Recordati’s geographic diversification was evident in its regional performance, with particularly strong momentum in the U.S. market offsetting weakness in certain European countries.
The following table provides a detailed breakdown of revenue by geography:
The U.S. market delivered exceptional growth of 29.5% to €312.4 million, or 38.2% growth in local currency terms to $364.4 million. This performance was driven primarily by the rare diseases portfolio, particularly Isturisa and Enjaymo, as well as the contribution from newly acquired products.
In Western Europe, performance was mixed. Spain showed strong growth of 12.2% to €123.9 million, while Portugal grew 4.9% to €37.5 million. Other Western European countries collectively increased 12.6% to €90.3 million. However, Italy declined 8.5% to €166.5 million, France fell 5.3% to €88.3 million, and Germany decreased 6.6% to €82.8 million, reflecting the impact of one-off headwinds including the Cardicor loss and product phasing effects.
Turkey delivered robust growth of 16.2% to €81.9 million, or 34.3% in local currency terms to 4,030.5 million Turkish lira, benefiting from the Eligard competitive situation and strong underlying demand. Russia and other CIS countries grew 7.7% to €87.4 million, or 7.0% in local currency, excluding rare disease products.
The company’s diversified geographic footprint is further illustrated in the following revenue composition chart:
This diversification across approximately 150 countries provides Recordati with natural hedges against regional market dynamics and regulatory changes, while also exposing the company to foreign exchange volatility, particularly from the U.S. dollar and Turkish lira.
Margin Expansion and Cash Flow Strength
One of the most notable aspects of Recordati’s first-half performance was the significant margin expansion across multiple profitability metrics, demonstrating operating leverage as the higher-margin rare diseases business grows as a percentage of total revenue.
The company’s cash flow performance showed marked improvement, as detailed in the following statement:
Cash flow from operating activities increased to €320.0 million from €272.2 million in the prior year, an improvement of €47.8 million. This was driven by the strong EBITDA performance of €540.2 million, up €43.9 million year-over-year. Working capital movements consumed €106.3 million, slightly higher than the prior year’s €102.9 million, while changes in other assets and liabilities contributed a positive €29.6 million compared to a use of €2.7 million in the prior year.
After accounting for capital expenditures of €20.6 million (net of disposals), free cash flow reached €299.4 million, up €42.6 million from €256.8 million in the first half of 2025. This represented a free cash flow yield of approximately 5% based on the company’s market capitalization of $11.9 billion.
The company deployed €143.2 million in dividend payments during the period, maintaining its track record of 13 consecutive years of dividend increases according to InvestingPro data. The current dividend yield stands at 2.61%. Additionally, Recordati generated €20.2 million from the net sale of treasury shares, compared to purchases of €48.4 million in the prior year.
The following breakdown shows how the company’s revenue and EBITDA are distributed across its two main operating segments:
While rare diseases represented 42.8% of total revenue, this segment contributed 48.2% of EBITDA, reflecting its superior profitability profile. The rare diseases segment achieved an EBITDA margin of 43.1%, compared to 34.7% for the specialty and primary care business. This margin differential underscores the strategic importance of continuing to grow the rare diseases portfolio.
R&D Pipeline and Strategic Initiatives
Recordati highlighted several important developments in its research and development pipeline that position the company for continued growth beyond its current marketed products.
The company’s comprehensive R&D program update is illustrated in the following overview:
A key announcement during the quarter was the new license agreement with Ionis Pharmaceuticals for exclusive development and commercialization rights to zilganersen, an investigational RNA-targeted medicine for the treatment of Alexander disease, in all countries outside the U.S. Alexander disease is an ultra-rare, progressive, and fatal neurological disorder with no approved treatments. Recordati plans to submit regulatory filings in Europe and Japan in the first quarter of 2027, pending successful study outcomes.
For Isturisa, the company is expanding its development program to address a broader patient population. A Phase IV study will evaluate the drug in patients with hypertension caused by hypercortisolemia due to Cushing’s syndrome, with enrollment initiation beginning in August 2026. This randomized, placebo-controlled trial will assess efficacy and safety in adults with mild hypercortisolemia and uncontrolled hypertension, potentially expanding the addressable market significantly beyond the current severe Cushing’s syndrome indication.
The study design includes a three-week screening period, an 18-week dose titration phase with patients randomized to either osilodrostat or placebo, and a 12-week stable dose phase. Primary endpoints include urinary-free cortisol levels, with blood pressure as a key secondary endpoint.
For Qarziba, the company is pursuing expansion into additional indications. Results from an interim analysis of an ongoing trial in high-risk relapsed/refractory neuroblastoma in the U.S. are expected in the first half of 2028 and could form the basis for a potential regulatory filing. Additionally, top-line results from an investigator-sponsored trial evaluating Qarziba’s safety, dose, and early signs of efficacy in Ewing sarcoma are expected in the fourth quarter of 2026.
Recordati is also advancing mRNA-3927 for propionic acidemia, with top-line results from a registrational clinical study expected by the end of 2026. This represents the company’s entry into the emerging field of mRNA therapeutics for rare metabolic disorders.
Product Portfolio and Revenue Drivers
The company’s diversified product portfolio spans multiple therapeutic areas, with several key products contributing significantly to overall performance.
The following detailed breakdown shows revenue for the company’s main products:
In the specialty and primary care segment, Zanidip and Zanipress (lercanidipine combinations) remained the largest contributor at €99.7 million, though revenue declined 6.4% due to mature product dynamics and competitive pressures. Eligard grew to €69.1 million, while Livazo (pitavastatin) posted strong 28.5% growth to €36.2 million, benefiting from strong demand in Russia and Turkey and brand repatriation in Spain.
Within rare diseases, Isturisa has emerged as the portfolio’s flagship product at €178.8 million, followed by Qarziba at €83.7 million, Enjaymo at €91.0 million, and Signifor at €68.8 million. These four products collectively generated €422.3 million in revenue, representing 70% of total rare disease sales and demonstrating the concentration of growth in key franchises.
Full-Year 2026 Outlook
Recordati confirmed its full-year 2026 financial targets, expressing confidence in the underlying business momentum despite some near-term headwinds.
The company’s confirmed guidance is detailed in the following overview:
For fiscal year 2026, Recordati expects net revenue of €2,730 million to €2,800 million, representing approximately 5.6% growth at the midpoint on a reported basis, or 9.1% growth at constant exchange rates. The company anticipates a foreign exchange headwind of approximately 3.5%, primarily from the U.S. dollar and Turkish lira.
Within this outlook, rare diseases are expected to deliver robust high-teen organic growth at constant exchange rates, driven by accelerating Isturisa growth in the Cushing’s syndrome market and continued momentum in hema-oncology products. The specialty and primary care segment is projected to show low single-digit organic growth at constant exchange rates, with management expecting a return to mid-single-digit growth in fiscal year 2027 as one-off headwinds, including the Cardicor license loss, anniversary.
EBITDA is targeted at €995 million to €1,030 million, representing a margin of approximately 36.5% on revenue. This margin target reflects continued efficiency initiatives and operating leverage from the growing rare diseases business, offset by increased investments behind the broader Isturisa Cushing’s syndrome opportunity in the U.S. The company expects a foreign exchange impact of approximately 4.0% on EBITDA.
Adjusted net income is projected at €655 million to €685 million, representing approximately 24.0% of revenue. Financial expenses are expected to be aligned with 2025 levels, with lower interest expenses offset by lower foreign exchange gains compared to the prior year.
Management emphasized that the guidance reflects a balanced view of the business, acknowledging both the strong momentum in rare diseases and the temporary headwinds affecting the specialty and primary care segment. The company’s net debt position below 1.9 times EBITDA provides flexibility for potential business development opportunities while maintaining a conservative balance sheet.
CEO Rob Koremans stated that "Rare Disease continues to be the key engine of our growth," while CFO Mike McClellan noted that the company’s free cash flow and balance sheet provide "considerable financial flexibility" for future investments. The company’s 13-year track record of consecutive dividend increases and current dividend yield of 2.61% underscore management’s confidence in the sustainability of cash generation.
With shares trading near the upper end of their 52-week range and a price-to-earnings ratio of 22.8, the market appears to have largely priced in the company’s solid execution and near-term growth prospects. The key question for investors will be whether Recordati can maintain its rare disease momentum while successfully navigating the return to growth in its larger specialty and primary care business in 2027 and beyond.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.